Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Cadrenal Therapeutics, Inc. ( (CVKD) ) is now available.
On February 24, 2026, Cadrenal Therapeutics reported results from a randomized, blinded, placebo-controlled Phase 2 trial of CAD-1005 in patients with heparin-induced thrombocytopenia, which concluded in December 2025 after transfer of the program from Veralox Therapeutics. The study, which ultimately enrolled 24 patients instead of the planned 60, showed that CAD-1005 did not improve platelet count recovery versus placebo, indicating that platelet recovery is not a reliable surrogate marker for clinical efficacy in this high-risk population.
Despite missing the primary endpoint, CAD-1005-treated patients experienced fewer thrombotic events than those on placebo, with events occurring in about half the CAD-1005 group versus more than three-quarters of the placebo arm, all on top of standard anticoagulant therapy. These secondary findings, though from a small and underpowered dataset, support CAD-1005’s mechanism as the only 12-LOX inhibitor in clinical development for HIT and underpin Cadrenal’s move toward a Phase 3 registration strategy, with an End-of-Phase 2 FDA meeting scheduled for March 2026 that could shape the drug’s path in a field long reliant on anticoagulants lacking robust randomized evidence.
The most recent analyst rating on (CVKD) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on Cadrenal Therapeutics, Inc. stock, see the CVKD Stock Forecast page.
Spark’s Take on CVKD Stock
According to Spark, TipRanks’ AI Analyst, CVKD is a Neutral.
The score is primarily held down by weak financial performance (no revenue, widening losses, and significant cash burn with likely external funding needs). Technicals are mixed but still skew negative versus longer-term moving averages, and valuation metrics are limited by losses. Offsetting these risks, recent corporate events modestly improve the outlook by strengthening the pipeline and leadership.
To see Spark’s full report on CVKD stock, click here.
More about Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company focused on novel therapies for life-threatening immune and thrombotic conditions. Its lead asset, CAD-1005, is a first-in-class 12-lipoxygenase inhibitor in development for heparin-induced thrombocytopenia, complemented by a broader pipeline that includes tecarfarin and frunexian for high-risk cardiovascular patients.
The company targets severe hospital-based clotting disorders and related indications where current anticoagulant options leave substantial residual risk. CAD-1005 has secured Orphan Drug and Fast Track status in the U.S., as well as orphan designation in Europe, underscoring its focus on rare but deadly immune-mediated thrombotic diseases.
Average Trading Volume: 57,156
Technical Sentiment Signal: Sell
Current Market Cap: $12.91M
For detailed information about CVKD stock, go to TipRanks’ Stock Analysis page.